We are delighted now to be able to meet demand from EU nations. We look forward to working with the military, emergency services, law enforcement, and rescue personnel throughout the EU.
BETHESDA, Md. (PRWEB) September 22, 2008
"As the most effective hemostatic agent available, we are seeing growing worldwide interest in WoundStat," said Devinder Bawa, CEO of TraumaCure. "We are delighted now to be able to meet demand from EU nations. We look forward to working with the military, emergency services, law enforcement, and rescue personnel throughout the EU."
The results of multiple independent studies, including those by the US Army, Navy and Air Force, have proven that WoundStat is the most effective hemostat available for high pressure arterial wounds. WoundStat consistently stopped arterial bleeding within seconds, resulted in the least amount of blood loss, and stabilized the wound for several hours. These qualities are essential to provide the time needed to seek advanced medical help and save lives.
TraumaCure received FDA clearance to sell WoundStat in August 2007 and ISO 13485 certification in June 2008. The company also recently announced it received a medical device license from Health Canada.
"CE Mark certification is a direct result of TraumaCure's efforts to ensure the global availability of a consistent, safe, and effective product that is ready to save lives, anytime and anywhere it is needed" commented Bawa.
TraumaCure, based in Bethesda, Maryland, supplies the most effective, reliable treatments for life-threatening bleeding wounds. TraumaCure's hemostatic products help stabilize a wounded individual prior to receiving advanced medical treatment. The company's products are made in the U.S. and are proven to save lives and improve outcomes following traumatic injury. TraumaCure is committed to providing the most trustworthy and innovative hemostasis treatments for the military, emergency responders, and civilians.